Alnylam Pharmaceuticals Inc (ALNY)vsDermata Therapeutics Inc (DRMA)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
DRMA
Dermata Therapeutics Inc
$1.55
-1.27%
HEALTHCARE · Cap: $4.67M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. DRMA trades at a lower P/E of 0.1x. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
DRMA
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+98.6%
Fair Value
$103.63
Current Price
$1.55
$102.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : DRMA
The strongest argument for DRMA centers on P/E Ratio, Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while DRMA is a value play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.60 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 23/100) and 84.9% revenue growth. DRMA offers better value entry with a 98.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead asset, DMT310, which utilizes a novel delivery system to improve treatment efficacy for acne and other skin disorders. The company is committed to addressing significant unmet needs in the dermatology market with a strategically designed pipeline aimed at advancing skin health. As Dermata navigates its clinical trials, it leverages proprietary technology to create effective, safe, and user-friendly therapeutic solutions that position it for leadership in the dermatological arena. With a strong emphasis on patient outcomes, Dermata is poised to make a meaningful impact in the treatment of skin-related issues.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?